natgillin/translations-raw huggingface dataset:
The method according to any one of the preceding claims, wherein the number of oil droplets having a size of >1.2 µm after filtration is 5 x 108 /ml or less. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um nakon filtracije je 5 x 105 /ml ili manje.
A solid cosmetic composition according to claim 13, wherein the soft vegetable butter is selected from aloe butter, avocado butter, cupuacu butter, macadamia nut butter, mango butter, olive butter, shea butter, coconut butter, pumpkin seed butter, peanut butter, almond butter, coffee bean butter, refined butter, hemp seed butter, mochacchino butter, pistachio nut butter, shealoe butter, and mixtures thereof, in an amount of 20 to 60 wt. %. 
Kruti kozmetički pripravak prema zahtjevu 9 ili 10, naznačen time što je mekani biljni maslac odabran od aloe maslaca, avokado maslaca, kupuaku maslaca, maslaca od makadamija oraščića, mango maslaca, maslaca od masline, shea maslaca, kokosovog maslaca, maslaca od sjemenki bundeve, kikiriki maslaca, te bademovog maslaca, maslaca od zrna kave, rafiniranog maslaca, maslaca od konoplje, Mochacchino maslaca, pistacio maslaca, Shealoe maslaca i njihovih smjesa. u količini od 20 do 60 mas. %.
The method of claim 5, wherein the removable cap includes a clip affixed to a rear portion of the removable cap, and further comprising clipping the air freshener device onto a vent in an automobile climate system. 
Postupak prema zahtjevu 5, naznačen time, da premjestiva kapica (112) obuhvaća kvačicu (110) koja je pričvršćena na stražnji dio premjestive kapice, i postupak dodatno obuhvaća zakvačenje uređaja za osvježivanje zraka na otvor za ventilaciju u automobilskom sustavu klimatizacije.
The compound of claim 4 having Formula XIV or Formula XV: or a pharmaceutically acceptable salt, or solvate thereof, wherein preferably: and W2 are N and W3 is CH; 
Tvar iz patentnog zahtjeva 4 koja ima formulu XIV ili formulu XV: Niw ili njena farmaceutski prihvatljiva sol ili solvat, gdje je poželjno da: W' i W? jesu N i W? je CH;
A salt of the compound of formula (I) according to claim 2 wherein the salt is an acid addition salt. 
Sol spoja formule (I) prema patentnom zahtjevu 1 pri čemu je sol adiciona sol kiseline.
Inhalers are sometimes coloured so as to indicate the medicament contained therein or the company, which manufactures the inhaler. 
Inhalatori su ponekad obojeni tako da se obilježi medikament koji se nalazi u njemu ili tvrtka koja proizvodi inhalator.
An immuno-stimulant combination according to any of claims 1 to 6 characterised in that all the components form part of at least two different pharmaceutical compositions. 
Imunostimulatorna kombinacija prema bilo kojem od patentnih zahtjeva 1 do 5 naznačena time što sve komponente formiraju dio najmanje dvije različite farmaceutske kompozicije.
wherein Ts represents p-toluenesulfonyl, Et represents ethyl, and R1 represents lower alkyl. 
[image] (u formuli Ts predstavlja p-toluensulfonil, Et predstavlja etil, a R1 predstavlja nerazgranati ili razgranati C1-6alkil).
is hydrogen, alkyl, or acyl; or a pharmaceutically acceptable salt thereof. 
R5 je vodik, alkil ili acil; ili njegova farmaceutski prihvatljiva sol.
forming budded virions (BVs), or ii) forming ODVs, which ODVs can be occluded in occlusion bodies or forming free ODVs not occluded in occlusion bodies. 
tvoreći pupajuće virione (BV), ili ii) tvoreći ODV, gdje ODV mogu biti okludirani u okluzijska tijela ili čine slobodne ODV koji nisu okludirani u okluzijska tijela.
The soft chewable veterinary composition of claim 7, wherein the humectant is glycerin, propylene glycol, cetyl alcohol or glycerol monostearate. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 7, naznačen time, da ovlaživač je glicerin, propilenglikol, cetilni alkohol ili glicerol-monostearat, još poželjnije glicerin.
In preferred embodiments the first engagement means is deflected radially outwardly after a predetermined degree or amount of rotation of the first ring member. The predetermined amount of rotation of the first ring member is associated with less than a full rotation of the first ring member about the common axis, for example a quarter rotation of the first ring member about the common axis. 
Brojač kao što je navedeno u zahtjevu 5 naznačeno time da se navedeno prvo sredstvo uključenja (704) radijalno deflektira prema van nakon predodređenog stupnja Totacije navedenog prvog prstenastog elementa (201), navedeni predodređeni stupanj rotacije navedenog prvog prstenastog elementa bivajući manji od pune rotacije navedenog prvog prstenastog elementa oko navedene zajedničke osi.
Process according to any one of paragraphs 35 to 37, wherein the at least one solvent is selected from alcohols, ketones, esters and ethers. Process according to paragraph 38, wherein the at least one solvent is selected from isopropyl acetate and tert-butyl methyl ether. 
Postupak prema zahtjevu 14ili 15, naznačen time, da barem jedno otapalo je odabrano od alkohola, ketona, estera i etera, i poželjno je odabrano od izopropil acetata i tert-butil metiletera.
flowing liquid into the container through the interior passage of the neck; 
(b) ulijevanje tekućine u spremnik kroz unutarnji prolaz u grlu;
Cetuximab or a variant thereof, binding the same epitope as Cetuximab; and 
(1i) Cetuksimab, ili njegova varijanta koja se veže na isti epitop kao Cetuksimab;
The method of claim 28, wherein the domain or peptide or polypeptide capable of eliciting an immune response is selected from autoantigens, tumor antigens, virus antigens, parasite antigens, bacterial antigens and immunogenic fragments thereof. 
Postupak prema zahtjevu 26 ili 28, naznačen time što se domena ili peptid ili polipeptid sa sposobnošću izazivanja imunog odgovora, bira između autoantigena, tumorskih antigena, virusnih antigena, antigena parazita, bakterijskih antigena i njihovih imunogenih fragmenata.
When the pressure differential reaches a certain level, the taps 18 are no longer able to resist the downwardly directed force and they bend or break causing the container 2 and the base unit 3 to move downwards. 
Kad razlika pritiska dosegne određenu razinu, nastavci 18 se više ne mogu oduprijeti sili usmjerenoj prema dolje i oni se savinu ili puknu i time uzrokuju da se spremnik 2 i osnovna jedinica 3 pomaknu prema dolje.
The use of an emulsion to make a vaccine or immune-modulating composition according to any one of claims 1 to 14, the use comprising: mixing an oil phase with an aqueous phase comprising a water-soluble polymer matrix material to form an emulsion, at least one of the oil phase and the aqueous phase comprising an active principle, wherein the active principle comprises an adjuvant which is a-galactosylceramide; and then 
Upotreba emulzije za pripravu kompozicije koja sadrži aktivnu tvar, upotreba sadrži: miješanje uljne faze s vodenom fazom da bi nastala emulzija; naznačeno time da uljna faza sadrži berem jedno ulje i najmanje jedan pospješivač topivosti; i
A biomass pyrolysis apparatus according to claim 5 wherein the heat transfer medium includes solid heat carrier balls. 
Uređaj za pirolizu biomase prema bilo kojem od zahtjeva 8 do 10, naznačen time, da medij za prijenos topline uključuje krute toplinske kuglice koje prenose toplinsku energiju.
IL-18BP is a soluble receptor that exist only as a secreted protein. 
IL-18BP? je topivi receptor koji se javlja isključivo kao izlučeni protein.
cooling a starting suspension comprising a lipid component and a protein component from a temperature in a first temperature range to a temperature in a second temperature range, wherein 
(a) hlađenje početne suspenzije koja sadrži lipidnu komponentu i proteinsku komponentu od temperature u prvom temperaturnom rasponu do temperature u drugom temperaturnom rasponu, naznačen time što:
The results are shown in Table 10. 
Rezultati su prikazani u Tabeli 10.
In table 2, R1 is an unsubstituted pyridin-4-yl group, p, m represent 2, o represents 1 and q represents 0. 
U Tablici 2: R1 je nesupstituirana piridin-4-ilna skupina ili nesupstituirana pirimidin-4-ilna skupina, p i m znače 2, o znači 1, a q znači 0.
Typical fatty acids are lauric acid, capric acid or oleic acid. 
Spoj prema patentnom zahtjevu 11, naznačen time što je masna kiselina oleinska kiselina ili laurinska kiselina.
The mixture is filtered, the solid is discarded and the solvent is evaporated to dryness to obtain 2,4-dichloro-3-methyl-benzenesulfonyl chloride as a crystalline white solid. 
Smjesa je filtrirana, krutina je odbačena, a otapalo je upareno do suha i dobiven je 2,4-diklor-3-metil-benzensulfonilklorid kao bijela kristalinična krutina.
wt.% to 30 wt.% of buprenorphine; wherein the composition transforms in situ into a solid implant by contact with water, body fluid, or other aqueous medium. 
tež.% do 30 tež.% buprenorfina; pri čemu se pripravak transformira in situ u čvrsti implantant u dodiru s vodom, tjelesnom tekućinom, ili drugim vodenim medijem.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound chlorothalonil. 
CH naznačen time da je R; difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj fludioksonil.
Method and apparatus for converting organic material 
METODA ZA PRETVORBU ORGANSKOG MATERIJALA U UGLJIKOHIDRANTNA GORIVA
and R3, taken separately, are independently H, -(C1-C4)alkyl, or -(C1-C4)perfluoroalkyl; or R2 and R3, taken together with the carbon to which they are attached, is -(C3-C6)cycloalkyl; 
(b) R? i R*, uzeti odvojeno, su neovisno H, -(C;-Co)alkil ili (C,-C.)perfluoralkil; ili R? i R, uzeti zajedno s ugljikom na kojeg su vezani, su (C3-Cg)cikloalkil;
Use according to any one of claims 1 to 8, characterised in that the compound is contained in the medicament in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 µg. 
Spoj za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je spoj kao sastojak lijeka u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 meg, najbolje od 100 ng do 100 ug.
Such a slot can be provided at any longitudinally extending side of the housing, and also at more than one side to provide a balanced drive force to the plunger. In fig. 10 is also shown a returnable object/ item 10 which has been positioned in the input receiving area, and which by the aid of gravity and the provision of the input opening 262 will fall into the interior space 261 of the housing, and thereby become located adjacent to the plunger 270 when the plunger initially has been positioned in a first position which is below the opening 262. 
141; 142) za opskrbu skladišta, i - pogon (280) klipa za pokretanje klipa u, i između, prvog i drugog položaja, navedeno transportno sredstvo je dalje prilagođeno tako da će povratni artikal koji je pozicioniran u ulazno područje a) pasti kroz ulazni otvor i u unutarnji prostor kada je klip pozicioniran u prvom položaju, i b) biti izbačen iz kućišta kroz navedeni otvor i prema otvoru za opskrbu skladišta pomoću klipa kad se klip dovede iz prvog položaja u drugi položaj.
A compound selected from the group consisting of 
Spoj izabran iz grupe koja se sastoji od a) spoja formule (C) [image] ili
This fuel/substrate combination was inserted 7 mm into a 70 mm foil lined tube which had a short cellulose acetate filter at the mouthend. 
Kombinacija gorivo/supstrat umetne se 7 mm u cijev od 70 mm koja je obložena sa [folijom koja je imala kratak filter od acetata celuloze na usnom kraju.
Since asenapine dissolves in the saliva the particle size is important. 
Budući se asenapin otapa u slini važna je veličina čestica.
Such a particle size can be obtained by means known in the art, for example by micronization. 
Takve veličine čestica se mogu dobiti načinima poznatim u struci, na primjer mikronizacijom.
Adjustable orthopaedic corset (10) according to claim 3, characterized in that the conjunction of the abdominal plates (44, 46) and the conjunction of the attaching plates (52, 54), among them and/or with respect to said abdominal plates (44, 46), is obtained through closing means of the Velcro type. 
Prilagodivi ortopedski korzet (10) u skladu s patentnim zahtjevom 3, karakteriziran na način da je veza abdominalnih pločica (44, 46) 1 veza pričvrsnih pločica (52, 54), između njih iili u odnosu na navedene abdominalne pločice (44, 46), postignuta putem sredstva zatvaranja Velcro tipa.
The results are shown in Table 2 below. 
Rezultati su prikazani u Tabeli ispod.
The compound according to claim 41 or a pharmacologically acceptable salt thereof, wherein A is a cyclohexyl group substituted by a methyl group or an ethyl group; and all of R4, R7, and R8 are a hydrogen atom. 
Spoj u skladu sa patentnim zahtjevom 31 ili njegova farmakološki prihvatljiva sol, gdje A je cikloheksil grupa supstituirana metil grupom ili etil grupom; i R4, R7, i R8 su svi atom vodika.
The system can then be deactivated as described above. 
Sustav tada može biti dezaktiviran na način kao što je gore opisano.
The compound or a salt thereof according to claim 1, wherein said compound is 2-fluoro-3-{3-[(6-methylpyridin-3-yl)oxy]azetidin-1-yl}benzyl carbamimidoylcarbamate, or a salt thereof. 
Spoj ili njegova sol prema zahtjevu 1, naznačen/a time, da navedeni spoj je 2-fluoro-3-[2-(3-metoksiazetidin-1-iI)pirimidin-5-il]benzil-karbamimidoilkarbamat, ili njegova sol.
A method for operating a voice communication apparatus (10), comprising: 
Postupak rada s uređajem za govornu komunikaciju (10), naznačen time što se sastoji u:
and the 3 alpha derivatives of the above identified 3 beta derivatives and also the corresponding 3 alpha and 3 beta thioderivatives where Y = S. 
kao i 3a-derivati gore nabrojanih 3B derivata, a također i odgovarajući 3a- i 3B-tioderivati, gdje Y = S.
The bishydrochloride monohydrate salt of the compound of formula (I) of any one of claims 1 or 2 or the pharmaceutical composition of claim 4 for use in the treatment or prevention of Parkinson's disease. 
Spoj prema bilo kojem od zahtjeva 1 do 3 ili farmaceutski sastav prema zahtjevu 5 za uporabu u liječenju ili sprečavanju Parkinsonove bolesti.
Drugs useful in the treatment of mental depression and apathy have generally fallen within at least one of three categories: (1) blockers of synaptosomal uptake of norepinephrine; (2) monoamine oxidase inhibitors; and (3) psychomotor stimulants. 
Lijekovi korisni u tretiranju mentalne depresije i apatije uglavnom spadaju u najmanje jednu od tri kategorije: (1) blokeri sinaptosomalne potrošnje norepinefrina; (2) inhibitori monoamin oksidaze; i (3) psihomotorni stimulanti.
Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). 
U takve formulacije mogu se također uključiti pomoćna sredstva veće molekularne mase kao što su celuloza (avicel) ili polietilen glikoli (PEG).
is selected from the group consisting of hydrogen, C1-3 alkyl, C3-6 cylcoalkyl, C4-5 alkylcycloalkyl, wherein C1-3 alkyl is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy or C1-6alkoxy; 
R, je izabran iz grupe koja se sastoji od vodika, C,3 alkil, Css cikloalkil, Cy s alkilcikloalkil, gdje je Ci13 alkil izborno supstituiran sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C,.galkoksi;
cutting said beam-like block of wood (12) to a veneer (14), drying said veneer obtained in step (iii) until the humidity content is below the fiber saturation point. 
(iv) sušenje navedenog furnira (14) koji je dobiven u fazi (iii) sve dok sadržaj vlage ne bude ispod točke zasićenja vlakana.
substituted and unsubstituted cycloalkyl; and is selected from the group consisting of hydrogen, and 
(D) supstituirani i nesupstituirani cikloalkil; i Ru je odabran iz skupine koja sadrži
In certain aspects, the human SAP polypeptide of the invention is a fusion protein comprising an SAP domain and one or more heterologous domains. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time, da je polipeptid fuzijski protein koji sadržava SAP domene i jednu ili više heterolognih domena.
GR20020100010 A PANAGIOTAKIS K. refers to a mechanism of honey extraction and therefore is irrelevant to my invention. 
GR 20020100010 PANAGIOTAKIS K. se odnosi na mehanizam ekstrakcije meda i stoga nije važan za moj izum.
and/or a physiologically acceptable salt thereof; 
i/ili njegova fiziološki prihvatljiva sol;
iii) greater than about 100 nucleotides in length. The nanoparticle of claim 6 or 7, wherein the molar ratio of the cargo molecule to the peptide in the nanoparticle is from about 1:1 to about 1:80, optionally wherein the molar ratio of the cargo molecule to the peptide in the nanoparticle is from about 1:5 to about 1:40; 
Nanočestica prema patentnom zahtjevu 6 ili 7, pri čemu je a) molarni omjer molekule tereta 1 peptida u nanočesticama je od oko 1:1 do oko 1:80, pri čemu je molarni omjer molekule tereta i peptida u nanočesticama opcijski od oko 1:5 do oko 1:40; b) molekula tereta je složena sa skupnom molekulom kako bi formirala jezgru nanočestice, pri čemu se skupna molekula opcijski odabire iz skupine koja se sastoji od peptida, proteina, antitijela, lipida, fosfolipida, polimera, aptamera, nanočestica, liposoma, dendrimera, polimerosoma, virusnog vektora i micele;
A patch of the ink was screen-printed on a white PVC support (100 g/m2) and the imprinted support was processed as described in example 1, except that the ink was dried in situ using an UV-radiation curing unit. 
Otisak tinte je otisnut zaslonom na bijeli nosač od PVC-a (100 g/m?), zatim se otisnuti nosač obradi na način opisan u primjeru 1, osim što se tinta osuši in situ pomoću uređaja za otvrdnjavanje UV-zrakama.
Neohesperidine DC (NHDC) is about 200 to 1500, and even 1800, times as sweet as sucrose on threshold levels, but it is, more importantly, a perfect flavour enhancer and masks the unpleasant aftertaste of AceK. 
Neohesperidin DC (NHDC) je oko 200 do 1500 puta slađi od saharoze u graničnim koncentracijama, no što je još važnije, izvrstan je pojačivač okusa i prikriva neugodan okus AceK koji ostaje nakon gutanja.
Of course, the peptide or variant according to the present invention will have the ability to bind to a molecule of the human MHC class I or II. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid ima sposobnost vezivanja s molekulom humanog glavnog kompleksa tkivne podudarnosti (MHC) klase I, 1 pri čemu navedeni peptid može stimulirati CD4 ili CD8 T- stanice.
A method of modifying a target DNA, the method comprising contacting the target DNA with a complex comprising: a Cas9 polypeptide; and 
Postupak moduliranja transkripcije specifične za mjesto unutar ciljane DNK, naznačen time, da postupak obuhvaća stavljanje u doticaj ciljane DNK s kompleksom koji obuhvaća sljedeće:
a domain from a Mycobacterium polypeptide, which is antigen (Ag) 85B or Ag85A, which is capable of eliciting an immune response, and 
(a) domenu iz polipeptida mikobakterije, koja je antigen (Ag) 85B ili Ag85A, koja može potaknuti imuni odgovor, i
wherein n is a natural number, i is a serial number of the sub-group; wherein N p 1 is the length of a reference sub-group sequence, ck is a basic sequence index of a sequence with a length of N p 1 determined by the sequence group k; wherein ri is a basic sequence index in the candidate sequence collection, and Ni is the length of a sequence in the candidate sequence collection; wherein mk,i is a variable dependent on the group number k and the sub-group number i; wherein the modu operation makes the modulo value included in (-mk,i/2, mk,i/2]; 
pri čemu n je prirodni broj, i je serijski broj podskupine; pri čemu Np1 je duljina referentne podskupine sekvence, ck je osnovni indeks sekvence za sekvencu sa duljinom Np1 koji je određen sa skupinom sekvence k; pri čemu ri je osnovni indeks sekvence u zbirci sekvenci kandidata, i Ni je duljina sekvence u zbirci sekvenci kandidata; pri čemu je mk,i varijabla ovisna o broju skupine k i broju podskupine i; pri čemu modu operator predstavlja vrijednost modula uključenu u (-mk,i/2, mk,i/2];
A compound of formula I according to claim 2 wherein the unsubstituted hetero-C5-C10aryl of R and R4 is selected from the group consisting of isobenzofuranyl, thienyl, and indolyl. 
Spoj formule I prema zahtjevu 1, naznačen time, da je spoj odabran iz skupine koja sadrži:
Polysorbate 60 or 80 affects the integrity of intestinal mucosa (Lieberman, H. A., Rieger, M. M. and Banker, G. S., Eds., Pharmaceutical Dosage Forms: Disperse Systems, 2nd ed., Vol. 
Polisorbat 60 ili 80 utječe na cjelovitost crijevne sluznice (Lieberman, H.A., Rieger, M.M, i Banker, G.S., Ur, Pharmaceutical Dosage Forms: Disperse Systems, 2. izd., Vol.
and room temperature overnight resulted in complete removal of the benzyl group. 
ina sobnoj temperaturi preko noći dovodi do kompletnog odvajanja benzil grupe.
Method according to claim 9, wherein the maximum welding current is 2.5 to 5 kiloamperes per square millimeter of the projection in projection perpendicular to the main surface of the first metal sheet. 
Postupak prema bilo kojem od zahtjeva 9-16, naznačen time, da je maksimalna struja zavarivanja od 2,5 do 5 kiloampera po kvadratnom milimetru bradavice(60) u bradavici koja je okomita na glavnu površinu (53) prvog lima (50).
post-fixing with a solution of formaldehyde; 
ispiranje otopinom pepsina;
It is believed that the non-crystallising sugars or non-crystallising sugar alcohols, particularly when used in the preferred proportions described herein, contribute to the glassy structure of the lozenges of the invention. 
Vjeruje se da ne-kristalizirajući Šećeri ili ne-kristalizirajući šećerni alkoholi, posebno kada se koriste u ovdje opisanim poželjnim proporcijama, doprinose staklastoj strukturi tableti prema izumu.
The composite stainless steel and wood barrel according to claim 1, wherein the barrel comprises metal legs (9) which, apart from providing stable positioning of the barrel, enables the barrels to be arranged in a row 10 cm apart from each other and is also used for raising the body of the barrel 40 cm from the ground, thus facilitating decantation. 
Kombinirana bačva od nehrđajućeg čelika i drva, prema patentnom zahtjevu 1, naznačena time da sadrži metalne nožice (9) koje, osim što daju stabilnosti bačvi, omogućavaju da se bačve slažu na udaljenosti od 10 cm jedna od druge 1 koje se također koriste za podizanje tijela bačve na visinu od 40 cm od tla, što olakšava dekantiranje vina.
The method of claim 7, wherein said opening is along a long side of the rectangular bag (20). 
Postupak iz patentnog zahtjeva 7, naznačen time, da se navedeni otvor nalazi na dužoj stranici pravokutne vrećice
at least one secure processing unit (11) adapted for processing sensitive data, wherein the first integrated circuit (10) is separated from the second integrated circuit (20); 
- najmanje jednu sigurnosnu procesorsku jedinicu (11), prilagođena za obradu osjetljivih podataka, gdje je prvi integrirani krug (10) odvojen od drugog integriranog kruga (20);
R5, at each occurrence, is independently hydrogen, alkyl, cycloalkyl, aryl, haloalkyl, COR2a, CO2R2a, SO2NR2R2a, or SO2R2a; R6, at each occurrence, is independently alkyl, cycloalkyl, aryl or heteroaryl, all of which may be optionally substituted with with R7, R7a, R7b, and R7c; and 
, uvijek kada se pojavljuje, je nezavisno vodik, alkil, cikloalkil, aril, haloalkil, COR2a, CO2R2a, SO2NR2R2a, ili SO2R2a;, uvijek kada se pojavljuje, je nezavisno alkil, cikloalkil, aril ili heteroaril, od čega sve po izboru može biti supstituirano s R7, R7a, R7b, i R7c; i
at least one collecting line (10) coupled between said at least one mobile suction means (3) and said at least one filtration means (7); 
- < najmanje jedan sabirni vod (10) spojen između navedenog najmanje jednog pokretnog usisnog sredstva (3) i navedenog najmanje jednog sredstva za filtriranje (7);